Efficacy of lopinavir-ritonavir combination therapy for the treatment of hospitalized COVID-19 patients: a meta-analysis

被引：11
作者：
Deng, Jiawen [1 ]
Zhou, Fangwen [1 ]
Houl, Wenteng [1 ]
Heybati, Kiyan [1 ,2 ]
Ali, Saif [1 ]
Chang, Oswin [1 ]
Silver, Zachary [3 ]
Dhivagaran, Thanansayan [1 ,4 ]
Ramaraju, Harikrishnaa Ba [1 ]
Wong, Chi Yi [1 ]
Zuo, Qi Kang [5 ,6 ]
Lapshina, Elizabeth [6 ]
Mellett, Madeline [6 ]
机构：
[1] McMaster Univ, Fac Hlth Sci, 1280 Main St W, Hamilton, ON L8S 4L8, Canada
[2] Mayo Clin, Alix Sch Med, 200 First St SW, Rochester, MN 55905 USA
[3] Carleton Univ, Fac Sci, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada
[4] McMaster Univ, Integrated Biomed Engn & Hlth Sci Program, 1280 Main St W, Hamilton, ON L85 4L8, Canada
[5] Rutgers New Jersey Med Sch, Dept Anesthesiol, 185 S Orange Ave, Newark, NJ 07103 USA
[6] McGill Univ, Fac Sci, 845 Sherbrooke St W, Montreal, PQ H3A 0G4, Canada
来源：
FUTURE VIROLOGY | 2022年 / 17卷 / 03期
基金：
英国科研创新办公室;
关键词：
adverse events; antiviral; covid-19; lopinavir; mortality; ritonavir; SARS-CoV-2; CLINICAL-EFFICACY; PUBLICATION BIAS; LOPINAVIR/RITONAVIR; DISEASE; GUIDELINES; QUALITY; SARS; HIV; PHARMACOKINETICS; INHIBITORS;
D O I：
10.2217/fvl-2021-0066
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Aim: To evaluate the efficacy and safety of lopinavir-ritonavir (LPV/r) therapy in treating hospitalized COVID-19 patients. Materials & methods: Data from randomized and observational studies were included in meta-analyses. Primary outcomes were length of stay, time for SARS-CoV-2 test conversion, mortality, incidence of mechanical ventilation, time to body temperature normalization and incidence of adverse events. Results: Twenty-four studies (n = 10,718) were included. LPV/r demonstrated no significant benefit over the control groups in all efficacy outcomes. The use of LPV/r was associated with a significant increase in the odds of adverse events. Conclusion: Given the lack of efficacy and increased incidence of adverse events, the clinical use of LPV/r in hospitalized COVID-19 patients is not recommended.
引用
收藏
页码：169 / 189
页数：21
相关论文
共 127 条
  • [61] Therapy for Early COVID-19 A Critical Need
    Kim, Peter S.
    Read, Sarah W.
    Fauci, Anthony S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (21): : 2149 - 2150
  • [62] Fast news or fake news? The advantages and the pitfalls of rapid publication through pre-print servers during a pandemic
    King, Anthony
    [J]. EMBO REPORTS, 2020, 21 (06)
  • [63] Kubin CJ., 2010, INFECT DIS 3, V2, P1434, DOI [10.1016/B978-0-323-04579-7.00145-3, DOI 10.1016/B978-0-323-04579-7.00145-3]
  • [64] Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
    Lecronier, Marie
    Beurton, Alexandra
    Burrel, Sonia
    Haudebourg, Luc
    Deleris, Robin
    Le Marec, Julien
    Virolle, Sara
    Nemlaghi, Safaa
    Bureau, Come
    Mora, Pierre
    De Sarcus, Martin
    Clovet, Olivier
    Duceau, Baptiste
    Grisot, Paul Henri
    Pari, Marie Helene
    Arzoine, Jeremy
    Clarac, Ulrich
    Boutolleau, David
    Raux, Mathieu
    Delemazure, Julie
    Faure, Morgane
    Decavele, Maxens
    Morawiec, Elise
    Mayaux, Julien
    Demoule, Alexandre
    Dres, Martin
    [J]. CRITICAL CARE, 2020, 24 (01)
  • [65] Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice
    Levy, Clementine
    Lassailly, Guillaume
    Parmentier, Erika
    Duburcq, Thibault
    Mathurin, Philippe
    Poissy, Julien
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 (10) : 1716 - 1718
  • [66] Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
    Li, Yueping
    Xie, Zhiwei
    Lin, Weiyin
    Cai, Weiping
    Wen, Chunyan
    Guan, Yujuan
    Mo, Xiaoneng
    Wang, Jian
    Wang, Yaping
    Peng, Ping
    Chen, Xudan
    Hong, Wenxin
    Xiao, Guangming
    Liu, Jinxin
    Zhang, Lieguang
    Hu, Fengyu
    Li, Feng
    Zhang, Fuchun
    Deng, Xilong
    Li, Linghua
    [J]. MED, 2020, 1 (01): : 105 - +
  • [67] Bias caused by sampling error in meta-analysis with small sample sizes
    Lin, Lifeng
    [J]. PLOS ONE, 2018, 13 (09):
  • [68] The dual role of anti-viral therapy in the treatment of Coronavirus disease 2019
    Liu, J-Y
    Hua, M-X
    Du, C-J
    Pu, L.
    Xiang, P.
    Li, C-S
    Xiong, H-F
    Liu, X-Z
    Chen, Z-H
    Xie, W.
    Li, A.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (22) : 11939 - 11944
  • [69] Sample Size and the Precision of the Confidence Interval in Meta-analyses
    Liu, Xiaofeng Steven
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2015, 49 (04) : 593 - 598
  • [70] Population Pharmacokinetics of Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients
    Lopez Aspiroz, Elena
    Santos Buelga, Dolores
    Cabrera Figueroa, Salvador
    Lopez Galera, Rosa Maria
    Ribera Pascuet, Esteban
    Dominguez-Gil Hurle, Alfonso
    Garcia Sanchez, Maria Jose
    [J]. THERAPEUTIC DRUG MONITORING, 2011, 33 (05) : 573 - 582
234567891011